Objective:To investigate the clinical efficacy of bromocriptine combined with endoscopic transsphenoidal resection for the treatment of pituitary tumors and its impact on patients'sex hormone levels.Methods:A total of 98 patients with pituitary tumors who were scheduled to undergo endoscopic transsphenoidal resection of the pituitary gland were selected for the study.They were divid-ed into a bromocriptine group and a control group according to whether bromocriptine was used before surgery,49 cases in each group.Both groups underwent endoscopic transsphenoidal resection of the pituitary gland,and the bromocriptine group was treated with bro-mocriptine three days before surgery,both groups was followed up for 3 months after surgery.The clinical efficacy,stress indicators[adrenaline(E),norepinephrine(NE),cortisol(R),and angiotensin Ⅱ(ATⅡ)levels],sex hormone levels[growth hormone(GH),prolactin(PRL),and thyroid stimulating hormone(TSH)],and quality of life(SF-36 score)before and after surgery were compared between the two groups.Results:The total effective rate of the bromocriptine group was higher than that of the control group's(95.92％vs.83.67％,P＜0.05).Compared with preoperative levels,the E,NE,R,and AT Ⅱ of both groups of patients increased 1 month after surgery(P＜0.05),the bromocriptine group was lower than the control group(P＜0.05).Compared with preoperative levels,both groups of patients showed a decrease in GH,PRL,and TSH levels(P＜0.05),and the bromocriptine group was lower than the control group(P＜0.05).At 1 and 3 months after surgery,the SF-36 scores of both groups of patients improved(P＜0.05),and bromocrip-tine group was higher than the control group(P＜0.05).Conclusion:The clinical efficacy of bromocriptine combined with endoscopic transsphenoidal resection for pituitary tumors is definite,which can effectively reduce the patient's sex hormone levels,stabilize the patient's postoperative stress indicators,and improve the patient's quality of life.